13-48307380-A-G
Variant summary
Our verdict is Benign. The variant received -7 ACMG points: 0P and 7B. BP4_ModerateBP6BS2
The NM_000321.3(RB1):c.238A>G(p.Lys80Glu) variant causes a missense change. The variant allele was found at a frequency of 0.0000118 in 1,613,454 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. K80N) has been classified as Likely benign.
Frequency
Consequence
NM_000321.3 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary retinoblastomaInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, G2P, Ambry Genetics
- retinoblastomaInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- melanomaInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -7 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| RB1 | NM_000321.3 | c.238A>G | p.Lys80Glu | missense_variant | Exon 2 of 27 | ENST00000267163.6 | NP_000312.2 | |
| RB1 | NM_001407165.1 | c.238A>G | p.Lys80Glu | missense_variant | Exon 2 of 27 | NP_001394094.1 | ||
| RB1 | NM_001407166.1 | c.238A>G | p.Lys80Glu | missense_variant | Exon 2 of 17 | NP_001394095.1 | ||
| RB1 | NM_001407167.1 | c.238A>G | p.Lys80Glu | missense_variant | Exon 2 of 3 | NP_001394096.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| RB1 | ENST00000267163.6 | c.238A>G | p.Lys80Glu | missense_variant | Exon 2 of 27 | 1 | NM_000321.3 | ENSP00000267163.4 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152238Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.00000796 AC: 2AN: 251344 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.0000123 AC: 18AN: 1461216Hom.: 0 Cov.: 31 AF XY: 0.0000165 AC XY: 12AN XY: 726970 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152238Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 74372 show subpopulations ⚠️ The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5.
Age Distribution
ClinVar
Submissions by phenotype
Retinoblastoma Uncertain:1Benign:1
This missense variant replaces lysine with glutamic acid at codon 80 of the RB1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in a pediatric individual affected with Ewing's sarcoma (PMID: 26580448). This variant has been identified in 2/251344 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Hereditary cancer-predisposing syndrome Uncertain:1
The p.K80E variant (also known as c.238A>G), located in coding exon 2 of the RB1 gene, results from an A to G substitution at nucleotide position 238. The lysine at codon 80 is replaced by glutamic acid, an amino acid with similar properties. This variant has been reported in 1/1120 pediatric cancer patients who underwent whole genome sequencing and/or whole-exome sequencing; this patient was diagnosed with Ewing's sarcoma (Zhang J et al. N Engl J Med, 2015 Dec;373:2336-2346). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at